Specialized Research FDA Phase 3

Mazdutide

Molecular Identifiers

Molecular Formula

C207H317N45O65

PubChem CID

167312357

Overview

Dual GLP-1/Glucagon agonist. Metabolic research. Gradual dose escalation recommended. Weekly administration.

In phase 3 clinical trials in China for the treatment of obesity and type 2 diabetes, developed by Innovent Biologics. Dual GLP-1/Glucagon agonist with results of up to 18% weight loss in Chinese studies.

Modified peptide — dual GLP-1/Glucagon agonist with chemical modifications for extended half-life

Half-life

~5-7 days

Administration Route

Subcutaneous

Category

Specialized Research

Mechanism of Action

  • GLP-1 receptor agonism (satiety, insulin secretion)
  • Glucagon receptor agonism (hepatic lipolysis, thermogenesis)
  • Dual effect for weight loss and glycemic control

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 3-6 mg per week (typically)
Frequency Once per week
Timing Same day/time each week
Duration 12-24 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Decreased appetite

Presentations & Preparation

Vials of Mazdutide found in the research market:

5 mg10 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: According to concentration
  • Inject the diluent slowly against the vial wall
  • Gently swirl until completely dissolved
  • Gradual dose escalation recommended

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Mazdutide.

2023 · Nat Commun

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Ji L, Jiang H, An P, Deng H, Liu M, Li L, et al.

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily